Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2781 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Angiotech announces cost cutting plans

Options to be explored, among others, include determining whether the company will be able to consummate its previously announced transaction with Ares Management and New Leaf Venture Partners,

Bristol-Myers Squibb raises ImClone bid

The offer is valued at approximately $4.7 billion, to equity holders of ImClone, other than Bristol-Myers Squibb. Bristol-Myers Squibb currently owns approximately 16.6% of all outstanding shares of